Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Eagle Pharmaceuticals total revenue increases by $2.5 million for Q2 2014

Eagle Pharmaceuticals, Inc. today announced its financial results for the three-month period ended March 31, 2014. This marks the first period for which Eagle is reporting financial results as a public company.

14 May 2014

Foundation Medicine obtains CE mark for FoundationOne

Foundation Medicine, Inc. today announced that it has obtained a CE mark for FoundationOne®. The CE mark allows FoundationOne to be placed on the market in the European Economic Area.

12 May 2014

Study of rare childhood neurodegenerative diseases identifies new source of DNA damage

St. Jude Children's Research Hospital scientists studying two rare, inherited childhood neurodegenerative disorders have identified a new, possibly common source of DNA damage that may play a role in other neurodegenerative diseases, cancer and aging.

12 May 2014

The Leukemia & Lymphoma Society passes $1 billion mark in blood cancer research investment

The Leukemia & Lymphoma Society announced that it has passed the $1 billion mark in research investment, a significant milestone in the cancer research landscape as LLS continues its 65 year pursuit of advancing breakthrough therapies, finding cures and ensuring access to life-saving therapies for all blood cancer patients.

8 May 2014

New technique expands number of functional cord blood stem cells for transplantation

Adults suffering from diseases such as leukemia, lymphoma, and other blood-related disorders may benefit from life-saving treatment commonly used in pediatric patients. Researchers at the Icahn School of Medicine at Mount Sinai have identified a new technique that causes cord blood (CB) stems cells to generate in greater numbers making them more useful in adult transplantation.

8 May 2014

ARIAD provides update on corporate developments, reports Q1 2014 financial results

ARIAD Pharmaceuticals, Inc. today reported financial results for the first quarter of 2014, including revenue from sales of Iclusig® (ponatinib) and licensing agreements. The Company also provided an update on corporate developments.

7 May 2014

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announced today results from the PRECiSE 3 7-year open label extension clinical trial of Cimzia (certolizumab pegol), the longest continuous trial of an anti-TNF therapy evaluating long-term safety in Crohn's disease.

6 May 2014

UAMS receives $1.8M grant to lead new treatments for herpes viruses and cancers

A surprise discovery that could lead to new treatments for herpes viruses that infect more than 90 percent of the world's adult population has led to a $1.8 million grant to the University of Arkansas for Medical Sciences (UAMS) from the National Cancer Institute (NCI) at the National Institutes of Health (NIH).

5 May 2014

LUNGevity Foundation welcomes FDA approval of Zykadia drug for advanced stages of lung cancer

LUNGevity Foundation applauds the FDA approval of Zykadia™ for the subset of anaplastic lymphoma kinase-positive (ALK+) patients with advanced cases of non-small cell lung cancer who have progressed on or are intolerant to crizotinib.

2 May 2014

Adhesion molecule offers promising therapeutic target for preventing colitis

May Provide Therapeutic Target for Treating Inflammatory Bowel Disease and Preventing Colitis-Associated Colorectal Cancer, According to New Research Published in The American Journal of Pathology

29 Apr 2014

Cell Therapeutics announces launch of PIXUVRI in the UK for treatment of aggressive B-cell NHL

Cell Therapeutics, Inc. today announced the launch of PIXUVRI (pixantrone), the first new treatment for adult patients in the United Kingdom (UK) with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL), at the 54th annual scientific meeting of the British Society for Haematology.

29 Apr 2014

Researchers uncover Noxa and MCL-1 as potential targets for small cell lung cancers therapies

Approximately 15 percent of all lung cancers are small cell lung cancers (SCLC), which grow rapidly and often develop resistance to chemotherapy. However, researchers at Virginia Commonwealth University Massey Cancer Center have revealed new insights into the mechanisms leading to this resistance that may lead to improved therapies.

25 Apr 2014

Scientists develop DNA nanodevices that survive body's immune defenses

It's a familiar trope in science fiction: In enemy territory, activate your cloaking device. And real-world viruses use similar tactics to make themselves invisible to the immune system.

23 Apr 2014

OncoSec to present update of data from Phase 2 melanoma study at ASCO Annual Meeting

OncoSec Medical Inc., a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, will present an update of data from their Phase 2 melanoma study at the American Society of Clinical Oncology's 50th Annual Meeting, taking place May 30-June 3, 2014, at McCormick Place in Chicago, Illinois.

22 Apr 2014

Ockham to partner with Leukemia and Lymphoma Society to increase commitment to cancer philanthropy

Ockham Development will partner with the Leukemia and Lymphoma Society of North Carolina chapter during 2014 to increase its commitment to cancer-directed philanthropy and collaborate with the Society to support the company's personal health and fitness goals.

22 Apr 2014

Study explains biological processes of malignant cancer cells

Cancer cells may be known for their uncontrollable growth and spread, but they also differ from normal tissue in another manner: how they produce energy.

22 Apr 2014

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

GlaxoSmithKline plc and Genmab A/S announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra® (ofatumumab), a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate.

21 Apr 2014

Researchers reveal connection between Down syndrome and acute lymphoblastic leukemia

Although doctors have long known that people with Down syndrome have a heightened risk of developing acute lymphoblastic leukemia (ALL) during childhood, they haven't been able to explain why. Now, a team of Dana-Farber Cancer Institute investigators has uncovered a connection between the two conditions.

21 Apr 2014

Boehringer grants volasertib 'orphan drug designation' for treatment of patients with AML

Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) and the European Commission have granted volasertib* 'orphan drug designation' for the treatment of patients with acute myeloid leukaemia (AML).

17 Apr 2014

MD Anderson honors America's future cancer leaders

The University of Texas MD Anderson Cancer Center this week honored 16 junior faculty members who are expected to become some of America's future cancer leaders. The faculty members are the first R. Lee Clark Fellow award winners. The new award was established to recognize outstanding work by junior faculty members and to help support their future efforts.

16 Apr 2014

Lymphoma News and Research

Further Reading

Eagle Pharmaceuticals total revenue increases by $2.5 million for Q2 2014

Foundation Medicine obtains CE mark for FoundationOne

Study of rare childhood neurodegenerative diseases identifies new source of DNA damage

The Leukemia & Lymphoma Society passes $1 billion mark in blood cancer research investment

New technique expands number of functional cord blood stem cells for transplantation

ARIAD provides update on corporate developments, reports Q1 2014 financial results

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UAMS receives $1.8M grant to lead new treatments for herpes viruses and cancers

LUNGevity Foundation welcomes FDA approval of Zykadia drug for advanced stages of lung cancer

Adhesion molecule offers promising therapeutic target for preventing colitis

Cell Therapeutics announces launch of PIXUVRI in the UK for treatment of aggressive B-cell NHL

Researchers uncover Noxa and MCL-1 as potential targets for small cell lung cancers therapies

Scientists develop DNA nanodevices that survive body's immune defenses

OncoSec to present update of data from Phase 2 melanoma study at ASCO Annual Meeting

Ockham to partner with Leukemia and Lymphoma Society to increase commitment to cancer philanthropy

Study explains biological processes of malignant cancer cells

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

Researchers reveal connection between Down syndrome and acute lymphoblastic leukemia

Boehringer grants volasertib 'orphan drug designation' for treatment of patients with AML

MD Anderson honors America's future cancer leaders

Everything you should know about lymphoma eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News